Course: Evolving Treatment Options in First-Line Metastatic Urothelial Carcinoma: Integrating the Latest Guidance and Evidence in Rural and Underserved Communities
CME Credits: 0.00
Released: 2024-12-13
While the outlook for patients with urothelial carcinoma has improved in urban areas, survival rates have remained unchanged in rural communities over the past two decades. Individuals who reside in these settings continue to experience limited access to advanced oncology care and slower adoption of new treatment guidelines, making management of late-stage disease more challenging. This CME/CE activity will review new and emerging monotherapy and combination therapy approaches for first-line treatment of metastatic and locally advanced urothelial carcinoma. Experts will also discuss evidence-based recommendations for recognizing, monitoring, and mitigating adverse events of therapy and strategies to enhance care coordination and shared decision-making for patients with urothelial carcinoma. This enduring activity is a recorded session from Oncology Congress that took place on September 28, 2024.
Upon completion of this activity, participants should be better able to:
View Full Course